Sepsis: a new look at the problem

Beloborodova N.V.

doi:https://doi.org/

Close metadata

Recommended articles:

New aspects of psoriasis pathogenesis: metabolomic profiling in dermatology. Russian Journal of Clinical Dermatology and Venereology. 2024;(5):526-531

Laboratory biomarkers for the prognosis of chronic heart failure. Laboratory Service. 2024;(3):5-16

Neurometabolic therapy with Cerebrolysin in patients with sepsis-associated encephalopathy. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):46-54

Nutritional support for sepsis: is there a single concept?. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):70-78

A balance between surgical management and therapy in a patient with severe sternomediastinitis complicated by heart failure and refractory septic shock. Pirogov Russian Journal of Surgery. 2024;(12-2):166-172

The role of neutrophils in the mechanisms of sepsis. Russian Journal of Archive of Pathology. 2024;(6):82-91

The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48

Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medicine. 2024;(12):145-150

Prognosis and prevention of recurrent and atypical endometrial hyperplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):59-65

Septic complications after abdominal delivery (literature review). Russian Journal of Human Reproduction. 2024;(6):108-117

Abstract:

The recent proceedings of congresses and forums on sepsis were used to write this review. The available definitions of sepsis and ideas on its etiology and pathogenesis are critically analyzed. There is information on new concepts of sepsis and data on a search for new targets, diagnostic and therapeutic approaches, and biomarkers. It is hypothesized that there is a mechanism of action of bacteria on mitochondrial dysfunction and human hormonal regulation with low-molecular weight exometabolites, namely aromatic microbial metabolites.

Keywords:

sepsis; international criteria; new concepts of sepsis; multiple organ dysfunction; mitochondrial dysfunction; biomarkers; microbial load; aromatic microbial metabolites

Authors:

Beloborodova N.V.

Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova, Moskva

Close metadata

References:

Bone R.C., Balk R.A., Cerra F.B. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009; 136 (Suppl 5): e28.
Sepsis v nachale XXI veka. Prakticheskoe rukovodstvo. Pod red. V.S. Savel'eva, B.R. Gel'fanda. M: Litterra 2006.
Sepsis: klassifikatsiya, kliniko-diagnosticheskaya kontseptsiya i lechenie. Prakticheskoe rukovodstvo. Pod red. V.S. Savel'eva, B.R. Gel'fanda. 2-e izd. M: MIA 2011.
Moroz V.V., Lukach V.N., Shifman E.M. i dr. Sepsis: kliniko-patofiziologicheskie aspekty intensivnoi terapii: rukovodstvo dlya vrachei. Petrozavodsk: IntelTek 2004.
Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39 (2): 165-228.
Fein A.M., Fink M.P., Bone R.C. et al. Sepsis and Multiorgan Failure. Philadelphia: Saunders 2002.
Bokeriya L.A., Beloborodova N.V. Infektsiya v kardiokhirurgii. M: NTsSSKh im. A.N. Bakuleva RAMN 2007.
Bernard G.R., Vincent J.L., Laterre P.F. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10): 699-709.
Vincent J.L., Abraham E. The last 100 Years of Sepsis. Am J Respir Crit Care Med 2006; 173 (3): 256-263.
Abraham E., Reinhart K., Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290 (2): 238-247.
Warren B.L., Eid A., Singer P. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286 (15): 1869-1878.
Ranieri V.M., Thompson B.T., Barie P.S. et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366 (22): 2055-2064.
Iba T., Aihara K., Watanabe S. et al. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thromb Res 2013; 131 (4): 295-299.
Saito H., Maruyama I., Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (1): 31-41.
A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. [Elektronnyi resurs]: http://www.artisanpharma.net/news.htm
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy. [Elektronnyi resurs]: http://clinicaltrials.gov/ct2/show/NCT01598831?term=ART-123&rank=2
Iba T., Nagaoka I., Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res 2013; 131 (5): 383-389.
Carlet J.M., Artigas A., Niederman M.S., Torres A. The Barcelona Declaration from the World Alliance against Antibiotic Resistance: engagement of intensivists. Crit Care 2012; 16 (4): 145.
Crowder F.M., Conly J.M., Surette M.G. A microbiome approach to sepsis: development and case-study application of novel methods for detection and isolation of microbes from whole blood. Critical Care 2012; 16 (Suppl 3): P111.
Puca E., Pipero P., Pilaca A. et al. Evaluation of procalcitonin in patients with sepsis in Albanian adults. Critical Care 2012; 16 (Suppl 3): P116.
McAllister K., Sheridan-Pereira M., O'Sullivan N. et al. Clinical utility of using C-reactive protein and procalcitonin as biomarkers for a novel neonatal sepsis diagnostic platform (ASCMicroPlat). Critical Care 2012; 16 (Suppl 3): P106.
Tang B.M.P., Eslick G.D., Craig J.C., McLean A.S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7 (3): 210-217.
Bouadma L., Luyt Ch.-E., Tubach F. at al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375 (9713): 463-474.
Afshari A., Harbarth S. Procalcitonin as diagnostic biomarker of sepsis. Lancet Infect Dis 2013; 13 (5): 382-384.
Cand C.W., Cand A.P., Brunkhorst F.M., Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (5): 426-435.
Jensen J.U., Hein L., Lundgren B. et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit. Crit Care Med 2011; 39: 2048-2058.
Riedel S. Procalcitonin and antibiotic therapy: Can we improve antimicrobial stewardship in the intensive care setting? Care Med 2012; 40 (8): 2499-2450.
Lassalle P., Freitas Caires N.De., Portier L. et al. Endothelial cell specific molecule 1 is today a relevant marker of respiratory failure in sepsis and polytrauma patients. Critical Care 2012; 16 (Suppl 3): P110.
Göschl J., Sudhoff L., Koehler M. et al. Is urinary kidney injury molecule-1 a good marker for acute kidney injury in septic shock? Critical Care 2012; 16 (Suppl 3): P59.
Gukasjan R., Raptis D., Schulz H.U. et al. Pancreatic stone protein: a new predictor of outcome in patients with peritonitis. Critical Care 2012; 16 (Suppl 3): P62.
Patent US 2011/0086381 A1, Katsuki Naito (Mochida Pharmaceutical Co., Ltd.)
Naito K., Shirakawa K., Naitou K. et al. The new sepsis marker, sCD14-ST, Induction mechanism in the rabbit sepsis models. Critical Care 2010; 14 (Suppl 2): P19.
Kuchler L., Morbitzer V., Heeg A. et al. Attenuated NOX2 expression impairs ROS production during the hypoinflammatory phase of sepsis. Critical Care 2012; 16 (Suppl 3): P51.
Crawford B., Skeath M., Kaiser W.A. Permanente Northern California sepsis mortality reduction initiative. Critical Care 2012; 16 (Suppl 3): P12.
Daneman N., Sarwar S., Fowler R.A., Cuthbertson B.H. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13 (4): 328-341.
Vincent J.L., Nelson D.R., Williams M.D. Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med 2011; 39 (5): 1050-1055.
Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348 (2): 138-150.
Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med 2007; 35 (Suppl 9): S441-448.
Singer M. Cellular Dysfunction in Sepsis. Clin Chest Med 2008; 29 (4): 655-660.
Frost M.T., Wang Q., Moncada S., Singer M. Hypoxia accelerates nitric oxide-dependent inhibition of mitochondrial complex I in activated macrophages. Am J Physiol Regul Integr Comp Physiol 2005; 288 (2): R394-400.
Gill S.R., Pop M., Deboy R.T. et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
Shenderov B.A. Modern condition and prospective host microecology investigations. Microb Ecol Health Dis 2007; 19: 145-149.
Shenderov B.A. Metabiotics: novel idea or naturaldevelopment of probiotic conception. Microb Ecol Health Dis 2013; 24: 20399. [Elektronnyi resurs]: http://dx.doi.org/10.3402/mehd.v24i0.20399
Patent na izobretenie "Sposob laboratornoi diagnostiki sepsisa" № 2423704 ot 10.07.2011. Beloborodova N.V., Olenin A.Yu., Khodakova A.S.
Fedotcheva N.I., Kazakov R.E., Kondrashova M.N., Beloborodova N.V. Toxic Effects of Microbial Phenolic Acids on the Functions of Mitochondria. Toxycology Letters 2008; 180: 182-188.
Fedotcheva N.I., Teplova V.V., Beloborodova N.V. Uchastie fenol'nykh kislot mikrobnogo proiskhozhdeniya v disfunktsii mitokhondrii pri sepsise. Biol membrany 2010; 1: 60-66.
Fedotcheva N.I., Teplova V.V., Beloborodova N.V. Rol' tiolovykh antioksidantov v vosstanovlenii funktsii mitokhondrii, modifitsirovannykh mikrobnymi metabolitami. Biofizika 2012; 5: 820-826.
Beloborodova N.V., Bairamov I.T., Olenin A.Yu., Fedotcheva N.I. Ekzometabolity nekotorykh anaerobnykh mikroorganizmov mikroflory cheloveka. Biomed khim 2011; 1: 95-105.
Beloborodova N.V., Bairamov I.T., Olenin A.Yu. i dr. Rol' mikrobnykh ekzometabolitov v gipoksicheskoi disfunktsii mitokhondrii pri sepsise. Patogenez 2011; 3: 19.
Beloborodova N.V. Integratsiya metabolizma cheloveka i ego mikrobioma pri kriticheskikh sostoyaniyakh. Obshchaya reanimatol 2012; 4: 42-54.
Beloborodova N.V., Olenin A.Yu., Khodakova A.S. i dr. Proiskhozhdenie i klinicheskoe znachenie nizkomolekulyarnykh fenol'nykh metabolitov v syvorotke krovi cheloveka. Anesteziol i reanimatol 2012; 5: 37-41.
Beloborodova N., Bairamov I., Olenin A. et al. Effect of phenolic acids of microbial origin on production of reactive oxygen species in mitochondria and neutrophils. J Biomed Sci 2012; 19: 89.
Beloborodova N.V., Olenin A.Y., Fedotcheva N.I. et al. Effect of phenolic acids originating from microbes on mitochondria and neutrophils. Critical Care 2012; 16 (Suppl 3): P26.